Critical Contrast: Madrigal Pharmaceuticals (MDGL) versus Raptor Pharmaceutical (RPTP)

Madrigal Pharmaceuticals (NASDAQ: MDGL) and Raptor Pharmaceutical (NASDAQ:RPTP) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, profitability, institutional ownership and earnings.

Earnings & Valuation

This table compares Madrigal Pharmaceuticals and Raptor Pharmaceutical’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Madrigal Pharmaceuticals N/A N/A -$31.15 million ($2.54) -46.13
Raptor Pharmaceutical N/A N/A N/A ($0.86) -10.47

Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than Raptor Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Madrigal Pharmaceuticals and Raptor Pharmaceutical, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Madrigal Pharmaceuticals 0 0 5 0 3.00
Raptor Pharmaceutical 0 0 0 0 N/A

Madrigal Pharmaceuticals presently has a consensus price target of $166.50, suggesting a potential upside of 42.09%. Given Madrigal Pharmaceuticals’ higher possible upside, research analysts clearly believe Madrigal Pharmaceuticals is more favorable than Raptor Pharmaceutical.

Institutional & Insider Ownership

36.0% of Madrigal Pharmaceuticals shares are owned by institutional investors. Comparatively, 54.9% of Raptor Pharmaceutical shares are owned by institutional investors. 66.4% of Madrigal Pharmaceuticals shares are owned by company insiders. Comparatively, 5.6% of Raptor Pharmaceutical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.


This table compares Madrigal Pharmaceuticals and Raptor Pharmaceutical’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Madrigal Pharmaceuticals N/A -37.46% -34.28%
Raptor Pharmaceutical -43.75% -77.01% -15.64%


Madrigal Pharmaceuticals beats Raptor Pharmaceutical on 5 of the 9 factors compared between the two stocks.

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc., formerly Synta Pharmaceuticals Corp., is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and nonalcoholic steatohepatitis (NASH). The Company’s lead product, MGL-3196, is a Phase II-ready once-daily, oral, liver-directed selective thyroid hormone receptor-b (THR-b) agonist for the treatment of NASH, and heterozygous and homozygous familial hypercholesterolemia (FH). Its product pipeline also includes MGL-3745, which is used in the treatment of NASH and FH. MGL-3196 has completed Phase I single and multiple dose trials in healthy volunteers. MGL-3196 is being developed for dyslipidemia/hypercholesterolemia to lower low-density lipoproteins cholesterol, triglyceride levels and lipoprotein(a). MGL-3196 also reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action.

About Raptor Pharmaceutical

Raptor Pharmaceutical Corp. (Raptor) is a biopharmaceutical company. The Company is focused on developing and commercializing transformative treatments for people affected by diseases. Its product, PROCYSBI (cysteamine bitartrate) is a delayed-release capsules for the management of nephropathic cystinosis in adults and children of over six years. In Europe, PROCYSBI gastro-resistant hard capsules of cysteamine (as mercaptamine bitartrate), is indicated as an orphan medicinal product for the management of nephropathic cystinosis. Its QUINSAIR is a formulation of the antibiotic drug levofloxacin, suitable for inhalation via a nebulizer. It is engaged in developing MP-376 for non-CF bronchiectasis (BE) and nontuberculous mycobacteria (NTM) lung infections. It is also engaged in developing RP105 and RP106 for various diseases.

Receive News & Ratings for Madrigal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Madrigal Pharmaceuticals and related companies with's FREE daily email newsletter.

Leave a Reply